NCT02735863View on ClinicalTrials.gov

ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

August 30, 2017

Study Completion Date

January 11, 2018

Conditions
HIV Infection
Interventions
DRUG

ABX464

50 mg or 150mg once daily for 28 days

DRUG

Placebo

ABX464 matching placebo

Trial Locations (8)

1000

C.H.U. Saint-Pierre, Brussels

4000

CHU Sart Tilman, Liège

9000

Ghent University Hospital, Ghent

69004

Hôpital de la Croix Rousse, Lyon

34 295

CHU de Montpellier - Hôpital Gui de Chauliac, Montpellier

08036

Hospital Clinic, Barcelona

08907

Hospital Universitari de Bellvitge, Barcelona

08916

Hospital Universitari Germans Trias i Pujo, Barcelona

Sponsors

Lead Sponsor

Abivax S.A.
All Listed Sponsors
lead

Abivax S.A.

INDUSTRY

NCT02735863 - ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment | Biotech Hunter | Biotech Hunter